Review reviewHigh

CVE-2026-50034

Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT)

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

CVSS
7.1
EPSS
0.21%
11.2% percentile
CISA KEV
Not listed
Published
2026.06.19
PRIORITY ASSESSMENT

Review review

The CVSS severity warrants an early asset and exposure review.

Known exploitationNot established by KEV
Exploit probability0.21%
Technical severityCVSS 7.1

Vulnerability overview

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

Affected product and versions

Product
Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT)
Affected versions
0x0110_v1.1.0
Fixed versions
No verified fixed-version field is available yet

Recommended response sequence

Confirm exposure before applying a vendor-supported change.

Full remediation guide
  1. 1
    Identify

    Confirm that Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT) and an affected version are present.

  2. 2
    Prioritize

    Combine exploitation signals with asset exposure and business criticality.

  3. 3
    Remediate

    Follow the vendor advisory or supported update path and preserve rollback options.

  4. 4
    Verify

    Recheck the version, service health, access paths, and relevant logs.

Technical data

CVSS vector
CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
CWE
CWE-319